
FDA Approves Bayer's Sunharbo as First Factor XIa Inhibitor, Cutting Recurrent Stroke 26% in a 12,327-Patient Trial
Asundexian, taken with antiplatelets, lowered ischemic stroke from 8.4% to 6.2% without a significant rise in major bleeding overall, but bleeding was higher in patients over 75 and in the first 90 days.




